TNYA vs. TCRX, PROK, KOD, LXEO, MGTX, AVXL, MESO, HUMA, IVVD, and PGEN
Should you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include TScan Therapeutics (TCRX), ProKidney (PROK), Kodiak Sciences (KOD), Lexeo Therapeutics (LXEO), MeiraGTx (MGTX), Anavex Life Sciences (AVXL), Mesoblast (MESO), Humacyte (HUMA), Invivyd (IVVD), and Precigen (PGEN). These companies are all part of the "medical" sector.
TScan Therapeutics (NASDAQ:TCRX) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.
TScan Therapeutics has higher revenue and earnings than Tenaya Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
TScan Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500.
82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 8.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 33.8% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Tenaya Therapeutics had 6 more articles in the media than TScan Therapeutics. MarketBeat recorded 8 mentions for Tenaya Therapeutics and 2 mentions for TScan Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.61 beat TScan Therapeutics' score of 0.35 indicating that TScan Therapeutics is being referred to more favorably in the media.
Tenaya Therapeutics has a net margin of 0.00% compared to Tenaya Therapeutics' net margin of -423.86%. Tenaya Therapeutics' return on equity of -60.65% beat TScan Therapeutics' return on equity.
TScan Therapeutics currently has a consensus price target of $12.50, suggesting a potential upside of 57.43%. Tenaya Therapeutics has a consensus price target of $15.40, suggesting a potential upside of 194.46%. Given TScan Therapeutics' higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than TScan Therapeutics.
Tenaya Therapeutics received 6 more outperform votes than TScan Therapeutics when rated by MarketBeat users. Likewise, 74.19% of users gave Tenaya Therapeutics an outperform vote while only 68.00% of users gave TScan Therapeutics an outperform vote.
Summary
Tenaya Therapeutics beats TScan Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Tenaya Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Tenaya Therapeutics Competitors List
Related Companies and Tools